• Prequel Prenatal Screen is a non-invasive prenatal screen (NIPS) with an industry-leading failure rate of 0.1%1
  • Prequel provides patients with more accurate, actionable information identifying more trisomy cases and reducing invasive diagnostic procedures compared to conventional screening2
  • ACOG, ACMG, and SMFM recognize or endorse NIPS for average-risk patients3,4

    Fact Sheets and Product Info:

    Executive Summary Download PDF


    About Prenatal Screening:

    Noninvasive prenatal screening provides important information.

    Most women get reassuring results that their pregnancy is at low risk for chromosome abnormalities. However, if a screen turns up something unusual, a healthcare provider will discuss what it means and will offer a follow-up diagnostic procedure to confirm the results. This may be chorionic villus sampling (CVS) or amniocentesis.

    The Prequel Prenatal Screen is a screening test, not a diagnostic test. This means it cannot give a definitive answer as to whether or not a pregnancy is affected by a chromosome condition. To confirm positive screening results, a follow-up diagnostic test will be needed and should be discussed with the patient’s provider.


    About Prequel Prenatal Screen:

    The Prequel Prenatal Screen is a noninvasive prenatal screen that uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for common chromosome abnormalities, such as Down syndrome.

    cfDNA screening has been shown to be superior to methods that use maternal age, ultrasound, and serum screening. This results in a lower false-positive rate and false-negative rate.5

    The Prequel Prenatal Screen can be ordered together with the Foresight® Carrier Screen and offered to all women, including those with high BMI, an ovum donor or a twin pregnancy.


    1. Hancock S, et al. Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate. Ultrasound Obstet Gynecol. 2020;56(3):422-430
    2. Bianchi DW, et al. DNA sequencing versus standard prenatal aneuploidy screening. NEJM.2014: 370(9):799-808
    3. ACOG Practice Bulletin No. 226: Screening for Fetal Chromosomal Abnormalities. Obstet Gynecol. 2020;136(4)
    4. Dungan J, et al, Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG), Genetics in Medicine (2022)
    5. Norton, M. et al Cell free DNA analysis for noninvasive examination of trisomy. The New England Journal of Medicine April 2015; 372: 1589-1597

    Myriad Products